Immunological aetiology of major psychiatric disorders: Evidence and therapeutic implications

Drugs

Volumn 65, Issue 11, 2005, Pages 1493-1520

  Sperner Unterweger, Barbara ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; AUTOANTIBODY; AZATHIOPRINE; BENZODIAZEPINE; CELECOXIB; CLOZAPINE; CORTICOSTEROID; CYTOKINE; HALOPERIDOL; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MEASLES MUMPS RUBELLA VACCINE; METHISOPRINOL; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; RISPERIDONE; TRANSFER FACTOR; TUMOR NECROSIS FACTOR ALPHA; VACCINE;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANXIETY DISORDER; ASEPTIC MENINGOENCEPHALITIS; AUTISM; AUTOIMMUNE DISEASE; BRAIN DISEASE; CYTOKINE RELEASE; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; ENCEPHALITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; MENTAL DISEASE; MOOD DISORDER; NEUROTRANSMISSION; NONHUMAN; PASSIVE IMMUNIZATION; PATIENT; REVIEW; SCHIZOPHRENIA; STRESS; SUBSTANCE ABUSE; SYSTEMIC LUPUS ERYTHEMATOSUS;

HUMANS; IMMUNE SYSTEM; MENTAL DISORDERS; PSYCHOTIC DISORDERS;

EID: 23744461373     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565110-00004     Document Type: Review

References (408)

1. Hofbauer B. Infecto psychica. Österr Med Wschr 1846; 39: 1183-5
2. Wollenberg R. Über psychische Infektion. Arch Psychiatr 1889; 20: 62
3. Bruce LC, Peebles AMS. Quantitative and qualitative leucocyte counts in various forms of mental disease. J Ment Sci 1904; 50: 409-17
4. Itten W. Zur Kenntnis hämatologischer Befunde bei einigen Psychosen. Zschr Ges Neurol Psychol 1914; 24: 341
5. Schultz J. Hämatologische Untersuchungsmethoden im Dienste der Psychiatrie. Dtsch Med Wschr 1913; 39: 1399
6. Damescheck W. The white blood cells in dementia praecox and dementia paralytica. Arch Neurol Psychiatry 1930; 24: 855
7. Sagel W. Einige Erfahrungen über das weiβe Blutbild und seinen Wert für die Psychiatrie. Zschr Ges Neurol Psychiatr 1930; 125: 436
8. Felten DL, Felten SY, Carlson SL, et al. Noradrenergic and peptidergic innervation of lymphoid tissue. J Immunol 1985; 135: 755-65
9. Friedman EM, Irwin MR. Modulation of immune cell function by the autonomic nervous system. Pharmacol Ther 1997; 73: 1-12
10. Rook GAW, Hernandez-Pando R, Lightman SL. Hormones, peripherally activated prohormones and regulation of Th1/Th2 balance. Immunol Today 1994; 15: 301-3
11. Buckingham JC, Gilies GE, Cowell AM, editors. Stress, stress hormones and the immune system. Chichester: John Wiley Ltd, 1997
12. Savino W, Dardenne M. Immune-endocrine interactions. Immunol Today 1995; 16: 318-22
13. Heath RG. Psychoneuroimmunology: an autoimmune pathogenesis for schizophrenia. Psychiatr Med 1990; 8: 95-110
14. Kirch DG. Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal. Schizophr Bull 1993; 19: 355-70
15. Menninger K. The schizophrenic syndrome as a product of acute infectious disease. Arch Neurol Psychiatry 1928; 20: 464
16. Goodall E. The existing cause of certain states, at present classified under 'schizophrenia' by psychiatrists may be infection. J Ment Sci 1932; 78: 746
17. Karlsson H, Bachmann S, Schröder J, et al. Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia. Proc Natl Acad Sci U S A 2001; 98: 4634-9
18. Albrecht P, Torrey EF, Boone E, et al. Raised cytomegalovirus-antibody level in cerebrospinal fluid of schizophrenic patients. Lancet 1980; II (8198): 769-72
19. Bartova L, Rajcani J, Pogady J. Herpes simplex antibodies in the cerebrospinal fluid of schizophrenic patients. Acta Virol 1987; 31: 443-6
20. Bechter K, Bauer M, Estler HC, et al. Erweiterte kernspintomographische Untersuchungen bei Borna-disease-Virus-seropositiven psychiatrischen Patienten und Kontrollen. Nervenarzt 1994; 65: 169-74
21. DeLisi LE, Smith SB, Harnovit JR, et al. Herpes simplex virus, cytomegalovirus and Epstein-Barr virus antibody titres in sera from schizophrenic patients. Psychol Med 1986; 16: 757-63
22. Fukuda R, Sasaki T, Kunugi H, et al. No changes in paired viral antibody titers during the course of acute schizophrenia. Neuropsychobiology 1999; 40: 57-62
23. Fux M, Sarov I, Ginot Y, et al. Herpes simplex virus and cytomegalovirus in the serum of schizophrenic patients versus other psychosis and normal controls. Isr J Psychiatry Relat Sci 1992; 29: 33-5
24. Hart DJ, Hearth RG, Sautter Jr FJ, et al. Antiretroviral antibodies: implications for schizophrenia, schizophrenia spectrum disorders and bipolar disorder. Biol Psychiatry 1999; 45: 704-14
25. Iwahashi K, Watanabe M, Nakamura K, et al. Clinical investigation of the relationship between Borna disease virus (BDV) infection and schizophrenia in 67 patients in Japan. Acta Psychiatr Scand 1997; 96: 412-5
26. King DJ, Cooper SJ, Earle J, et al. A survey of serum antibodies to eight common viruses in psychiatry patients. Br J Psychiatry 1985; 147: 137-44
27. King DJ, Cooper SJ, Earle JA, et al. Serum and CSF antibody titres to seven common viruses in schizophrenic patients. Br J Psychiatry 1985; 147: 145-9
28. Pandurangi AK, Pelonero AL, Nadel L, et al. Brain structure changes in schizophrenics with high serum titers of antibodies to herpes virus. Schizophr Res 1994; 11: 245-50
29. Pelonero AL, Pandurangi AK, Calabrese VP. Autoantibodies to brain lipids in schizophrenia. Am J Psychiatry 1990; 147: 661-2
30. Richt JA, Alexander RC, Herzog S, et al. Failure to detect Borna disease virus infection in peripheral blood leukocytes from humans with psychiatric disorders. J Neurovirol 1997; 3: 174-8
31. Rimon R, Nishimi M, Halonen P. Serum and CSF antibody levels to herpes simplex type I, measles and rubella viruses in patients with schizophrenia. Ann Clin Res 1978; 10: 291-3
32. Shrikhande S, Hirsch SR, Coleman JC, et al. Cytomegalovirus and schizophrenia: a test of a viral hypothesis. Br J Psychiatry 1985; 146: 503-6
33. Torrey EF, Peterson MR, Brannon WL, et al. Immunoglobins and viral antibodies in psychiatric patients. Br J Psychiatry 1978; 132: 342-8
34. Torrey EF, Yolken RR, Winfrey CJ. Cytomegalovirus antibody in cerebrospinal fluid of schizophrenic patients detected by enzyme immunoassay. Science 1982; 216: 892-4
35. Waltrip RW, Buchanan RW, Carpenter WT, et al. Borna disease virus antibodies and the deficit syndrome of schizophrenia. Schizophr Res 1997; 23: 253-7
36. Yamaguchi K, Sawada T, Naraki T, et al. Detection of borna disease virus-reactive antibodies from patients with psychiatric disorders and from horses by electrochemiluminescence immunoassay. Clin Diagn Lab Immunol 1999; 6: 696-700
37. DeLisi LE. Critical overview of current approaches to genetic mechanisms in schizophrenia research. Brain Res Brain Res Rev 2000; 31: 187-92
38. DeLisi LE. Is there a viral or immune dysfunction etiology to schizophrenia? Re-evaluation a decade later. Schizophr Res 1996; 22: 1-4
39. Pearce BD. Schizophrenia and viral infection during neurodevelopment: a focus on mechanisms. Mol Psychiatry 2001; 6: 634-46
40. Jablensky A. Schizophrenia: recent epidemiologic issues. Epidemiol Rev 1995; 17: 10-20
41. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia, manifestations, incidence and course in different cultures: a World Health Organization ten-country study. Psychol Med Monogr Suppl 1992; 20: 1-97
42. Torrey EF. Prevalence studies in schizophrenia. Br J Psychiatry 1987; 150: 598-608
43. Baldwin J. Schizophrenia and physical disease. Psychol Med 1979; 9: 611-8
44. Spector TD, Silman AJ. Does the negative association between rheumatoid arthritis and schizophrenia provide clues to the etiology of rheumatoid arthritis? Br J Rheumatol 1987; 26: 307-10
45. Vinogradov S, Gottesman II, Moises H, et al. Negative association between schizophrenia and rheumatoid arthritis. Schizophr Bull 1991; 17: 669-78
46. Eaton WW, Hayward C, Ram R. Schizophrenia and rheumatoid arthritis: a review. Schizophr Res 1992; 6: 181-92
47. Rubinstein G. Hypothesis: schizophrenia, rheumatoid arthritis and natural resistance genes. Schizophr Res 1997; 25: 177-81
48. Torrey EF, Yolken RH. The schizophrenia: rheumatoid arthritis connection: infectious, immune or both? Brain Behav Immun 2001; 15: 401-10
49. Torrey E, Torrey B, Petersen M. Seasonality of schizophrenic births in the United States. Arch Gen Psychiatry 1977; 34: 1065-70
50. Watson S, Kucala T, Tilleskjor C. Schizophrenic births seasonality in relation to the incidence of infectious diseases and temperature extremes. Arch Gen Psychiatry 1984; 41: 85-90
51. Pulver AE, Kung-Lee Y, Wolniec PS. Season of birth of siblings of schizophrenic patients. Br J Psychiatry 1992; 160: 71-5
52. Mednick SA, Huttunen MO, Machon RA. Prenatal influenza infections and adult schizophrenia. Schizophr Bull 1994; 20: 263-7
53. Torrey EF, Yolken RH. Familial and genetic mechanisms in schizophrenia. Brain Res Brain Res Rev 2000; 31 (2-3): 113-7
54. Weinberger DR. Schizophrenia: from neuropathology to neurodevelopment. Lancet 1995; 346: 552-7
55. Lehmann-Facius H. Über die Liquordiagnose der Schizophrenien. Klin Wochenschr 1937; 16: 1646-8
56. Kuznetoza NI, Semenov SF. Detection of antibrain antibodies in the sera of patients with neuropsychiatric disorders. Zh Nevropatol Psikhiatr Im S S Korsakova 1961; 61: 869-73
57. Fessel WJ. Autoimmunity and mental illness. Arch Gen Psychiatry 1962; 6: 320-3
58. Fessel WJ. The "antibrain factors" in psychiatric patients sera: I. Further studies with a hemaglutination technique. Arch Gen Psychiatry 1963; 8: 110-7
59. Heath RG, Krupp IM. Schizophrenia as an immunologic disorder: I. demonstration of antibrain globulins by fluorescent antibody techniques. Arch Gen Psychiatry 1967; 16: 1-9
60. DeLisi LE, Weber RJ, Pert CB. Are there antibodies against brain in sera from schizophrenic patient? Review and prospectus. Biol Psychiatry 1985; 20: 110-5
61. Pandey RS, Gupta AK, Chaturvede UC. Autoimmune model of schizophrenia with special reference to antibrain antibodies. Biol Psychiatry 1981; 16: 1123-36
62. Rothermundt M, Arolt V, Bayer TA. Review of immunological and immunopathological findings in schizophrenia. Brain Behav Immun 2001; 15: 319-39
63. Schwarz MJ, Chiang S, Müller N, et al. T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav Immun 2001; 15: 340-70
64. Ganguli R, Brar JS, Rabin BS. Immune abnormalities in schizophrenia: evidence for the autoimmune hypothesis. Harv Rev Psychiatry 1994; 2: 70-83
65. Schwarz MJ, Riedel M, Gruber R, et al. Autoantibodies against 60-kDa heat shock protein in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1998; 248: 282-8
66. Leykin I, Spivak B, Weizman A, et al. Elevated cellular immune response to human heat-shock protein-60 in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 1999; 249: 238-46
67. Kim YK, Kim L, Lee MS. Relationship between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res 2000; 44: 165-75
68. Theodoropoulou S, Spanakos G, Baxevanis CN, et al. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr Res 2001; 47: 13-25
69. Müller N, Schlesinger BC, Hadjamu M, et al. Increased frequency of CD8 positive gamma/delta T-lymphocytes (CD8+γ/δ+) in unmedicated schizophrenic patients: relation to impairment of the blood-brain barrier and HLA-DPA*02011. Schizophr Res 1998; 32: 69-71
70. Müller N, Riedel M, Hadjamu M, et al. Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia. Am J Psychiatry 1999; 156: 634-6
71. Schwarz MJ, Riedel M, Gruber R, et al. Antibodies to heat shock proteins in schizophrenic patients: implications for the mechanism of the disease. Am J Psychiatry 1999; 156: 1103-4
72. Ahokas A, Koskiniemi ML, Vaheri A, et al. Altered white cell count, protein concentration and olioclonal IgG bands in the cerebrospinal fluid of many patients with acute psychiatric disorders. Neuropsychobiology 1985; 14: 1-4
73. Kirch DG, Kaufmann CA, Papadopoulos NM, et al. Abnormal cerebrospinal fluid protein indices in schizophrenia. Biol Psychiatry 1985; 20: 1039-46
74. Müller N, Ackenheil M. Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: relationship to negative symptomatology. Schizophr Res 1995; 14: 223-8
75. DeLisi LE, Goodman S, Neckers LM, et al. An analysis of lymphocyte subpopulations in schizophrenic patients. Biol Psychiatry 1982; 17: 1003-9
76. Printz DJ, Strauss DH, Goetz R, et al. Elevation of CD5+ B lymphocytes in schizophrenia. Biol Psychiatry 1999; 46: 110-8
77. McAllister CG, Rapaport MH, Pickar D, et al. Increased numbers of CD5+ B lymphocytes in schizophrenic patients. Arch Gen Psychiatry 1989; 46: 890-4
78. Arnason BWG. Autoimmune diseases of the central and peripheral nervous systems. In: Rose NR, Mackay IR, editors. The autoimmune diseases. San Diego (CA): Academic Press, 1998: 571-602
79. Knight J. Possible autoimmune mechanisms in schizophrenia. Integr Psychiatry 1985; 3: 134-7
80. Knight J, Knight A, Ungvari G. Can autoimmune mechanisms account for the genetic predisposition to schizophrenia? Br J Psychiatry 1992; 160: 533-40
81. Murray RM, Jones P, O'Callaghan E, et al. Genes, viruses and neurodevelopmental schizophrenia. Arch Gen Psychiatry 1987; 44: 660-9
82. Abel L, Dessein AJ. The impact of host genetics on susceptibility to human infectious diseases. Curr Opin Immunol 1997; 9: 509-16
83. Arolt V, Rothermundt M, Wandinger KP, et al. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry 2000; 5: 150-8
84. Gaughran F, O'Neill E, Sham P, et al. Soluble interleukin 2 receptor levels in families of people with schizophrenia. Schizophr Res 2002; 56: 235-9
85. Tanaka KF, Shintani F, Fujii Y, et al. Serum inerleukin-18 levels are elevated in schizophrenia. Psychiatr Res 2000; 96: 75-80
86. Zhang XY, Zhou DF, Zhang PY, et al. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 2002; 57: 247-58
87. Achiron A, Noy S, Lereya J, et al. T-cell subsets in acute psychotic schizophrenic patients. Biol Psychiatry 1994; 35: 27-31
88. Bessler H, Eviatar J, Meshulam M, et al. Theophylline-sensitive T-lymphocyte subpopulation in schizophrenic patients. Biol Psychiatry 1987; 22: 1025-8
89. Coffey CE, Sullivan JL, Rice JR. T lymphocytes in schizophrenia. Biol Psychiatry 1983; 18: 113-9
90. Dvorakova M, Zvolsky P, Herzog P. Endogenous psychoses and T and B lymphocytes. Folia Haematol Int Mag Klin Morphol Blutforsch 1980; 107: 221-8
91. Ganguli R, Rabin BS, Raghu U, et al. T lymphocytes in schizophrenics and normals and the effects of varying antipsychotic dosage. In: Kurstak LM, editor. Viruses, immunity, and mental disorders. New York: Plenum Medical, 1987: 187-9
92. Ganguli R, Brar JS, Chengappa KMR, et al. Autoimmunity in schizophrenia: a review of recent findings. Ann Med 1993; 25: 489-96
93. Henneberg A, Riedl B, Dumke HO, et al. T-lymphocyte subpopulations in schizophrenic patients. Eur Arch Psychiatry Neurol Sci 1990; 239: 283-4
94. Masserini C, Vita A, Basile R, et al. Lymphocyte subsets in schizophrenic disorders: relationship with clinical, neuro-morphological and treatment variables. Schizophr Res 1990; 3: 269-75
95. Müller N, Ackenheil M, Hofschuster E, et al. Cellular immunity in schizophrenic patients before and during neuroleptic treatment. Psychiatry Res 1991; 37: 147-60
96. Nyland H, Naess A, Lunde H. Lymphocyte subpopulations in peripheral blood from schizophrenic patients. Acta Psychiatr Scand 1980; 61: 313-8
97. Rogozhnikova OA. Status of the T-lymphocyte system of im munity in patients with newly diagnosed paroxysmal schizophrenia. Zh Nevropatol Psikhiatr Im S S Korsakova 1991; 91: 47-9
98. Saifulina NA, Arkhipov GS, Stepanov AF, et al. T- and B-lymphocytes and their clinico-pathogenetic significance in patients with paranoid schizophrenia. Zh Nevropatol Psikhiatr Im S S Korsakova 1990; 90: 87-90
99. Schindler L, Leroux M, Beck J, et al. Studies of cellular immunity, serum interferon titers and of natural killer cell activity in schizophrenic patients. Acta Psychiatr Scand 1985; 72: 45-9
100. Tsukasa S, Shinichiro N, Rimmei F, et al. Changes of immunological functions after acute exacerbation in schizophrenia. Biol Psychiatry 1994; 35: 173-8
101. Vartanian ME, Koliaskina GI, Lozovsky DV, et al. Aspects of humoral and cellular immunity in schizophrenia. Birth Defects 1978; 14: 339-64
102. Zarrabi MH, Zucker S, Miller T, et al. Immunological and coagulation disorders in chlorpromazine-treated patients. Ann Intern Med 1979; 91: 194-9
103. Sperner-Unterweger B, Whitworth A, Kemmler G, et al. T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients. Schizophr Res 1999; 38: 61-70
104. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000; 157: 683-94
105. Mehler MF, Kessler JA. Cytokines in brain development and function. Adv Protein Chem 1998; 52: 223-51
106. Van Kammern DP, McAllister-Sistilli CG, Kelley ME, et al. Elevated interleukin-6 in schizophrenia. Psychiatry Res 1999; 87: 129-36
107. Frommberger UH, Bauer J, Haselbauer P, et al. Interleukin-6 (IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997; 247: 228-33
108. Naudin J, Capo C, Guisano B, et al. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia. Schizophr Res 1997; 26: 227-33
109. Kim YK, Lee MS, Suth KY. Decreased interleukin-2 production in Korean schizophrenic patients. Biol Psychiatry 1998; 43: 701-4
110. Lin A, Kenis G, Bignotti S, et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 1998; 32: 9-15
111. Akiyama K. Serum levels of soluble IL-2 receptor α, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr Res 1999; 37: 97-106
112. Maes M, Delange J, Ranjan R, et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatr Res 1997; 66: 1-11
113. Maes M, Chiavetto LB, Bignotti S, et al. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol 2000; 10: 119-24
114. Maes M, Chiavetto LB, Bignotti S, et al. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr Res 2002; 54: 281-91
115. Kowalski J, Blada P, Kucia K, et al. Neuroleptics normalize increased release of interleukin-1β and tumor necrosis factor-α from monocytes in schizophrenia. Schizophr Res 2001; 50: 169-75
116. Cazullo CL, Sacchetti E, Galluzzo A, et al. Cytokine profiles in drug-naive schizophrenic patients. Schizophr Res 2001; 47: 292-8
117. McAllister C, van Kammen DP, Rehn TJ, et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 1995; 152: 1291-7
118. Bessler H, Levental Z, Karp L, et al. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol Psychiatry 1995; 38: 297-302
119. Ganguli R, Brar JS, Chengappa KR, et al. Mitogen-stimulated interleukin-2 production in never-medicated, first episode schizophrenics: the influence of age of onset and negative symptoms. Arch Gen Psychiatry 1995; 52: 878
120. Cazzullo CL, Scarone S, Grassi B, et al. Cytokines production in chronic schizophrenia patients with or without paranoid behavior. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 947-57
121. Wilke I, Arolt V, Rothermundt M, et al. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 1996; 246: 279-84
122. Rothermundt M, Arolt V, Weitzsch CH, et al. Production of cytokines in acute schizophrenic psychosis. Biol Psychiatry 1996; 40: 1294-7
123. Mittelman BB, Castellanos FX, Jacobson LK, et al. Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J Immunol 1997; 159: 2994-9
124. Müller N, Riedel M, Ackenheil M, et al. The role of immune function in schizophrenia: an overview. Eur Arch Psychiatry Clin Neurosci 1999; 249 Suppl. 4: IV/62-8
125. Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994; 89: 346-51
126. Maes M, Bosmans E, Calabrese J, et al. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 1995; 29: 141-52
127. Gaughran F, O'Neill E, Cole M, et al. Increased soluble interleukin-2 receptor levels in schizophrenia. Schizophr Res 1998; 29: 263-7
128. Zalcman S, Green-Johnson JM, Murray L, et al. Cytokine-specific central monoamine alterations induces by IL-1, -2 and -6. Brain Res 1994; 643: 40-9
129. Jarskog LF, Xiao H, Wilkie MB, et al. Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro. Int J Dev Neurosci 1997; 15: 711-6
130. Merrill JE. Tumor necrosis factor alpha, interleukin-1 and related cytokines in brain development: Normal and pathological. Dev Neurosci 1992; 14: 1-10
131. Mehler MF, Kessler JA. Hematolymphopoetic and inflammatory cytokines in neural development. Trends Neurosci 1997; 20: 357-65
132. Licinio J, Seibyl JP, Altemus M, et al. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry 1993; 150: 1408-10
133. Marx CE, Jarskog F, Lauder JM, et al. Cytokine effects on cortical neuron MAP-2 immunoreactivity: implications for schizophrenia. Biol Psychiatry 2001; 50: 743-9
134. Boccio Chiavetto L, Boin F, Zanardini R, et al. Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. Biol Psychiatry 2002; 51: 480-4
135. Katila H, Hanninen K, Hurme M. Polymorphisms of the interleukin-1 gene complex in schizophrenia. Mol Psychiatry 1999; 4: 179-81
136. Boin F, Zanardini R, Pioli R, et al. Association between -G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. Mol Psychiatry 2001; 6: 79-82
137. Buka SL, Tsang MT, Torrey F, et al. Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry 2001; 58: 1032-7
138. Brown AS, Schaefer CA, Wyatt RJ, et al. Maternal exposure to respiratory infections and adult schizohrenia spectrum disorders: a prospective birth cohort study. Schizophr Bull 2001; 26: 287-95
139. Patterson PH. Maternal infection: window on neuroimmune interactions in fetal brain development and mental illness. Curr Opin Neurobiol 2002; 12: 115-8
140. Brown AS, Begg MD, Gravenstein S, et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 2004; 61: 774-80
141. Van Reeth K. Cytokines in the pathogenesis of influenza. Vet Microbiol 2000; 74: 109-16
142. Urakubo A, Jarskog F, Lieberman JA, et al. Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid and fetal brain. Schizohr Res 2001; 47: 27-36
143. Plata-Salaman CR, Iiyin SE, Gayle D, et al. Persistent Borna disease virus infection of neonatal rats causes brain regional changes of mRNAs for cytokines, cytokine receptor components and neuropeptides. Brain Res Bull 1999; 49: 441-51
144. Pearce BD, Valadi NM, Po CL, et al. Viral infection of developing GABAergic neurons in a model of hippocampal disinhibition. Neuroreport 2000; 11: 2433-8
145. Brown AS, Hooton J, Schaefer CA, et al. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult off spring. Am J Psychiatry 2004; 161: 889-95
146. Barrelet L, Ferrero F, Szigrthy L, et al. Expressed emotions and first-admission schizophrenia: nine-month follow-up in a French cultural environment. Br J Psychiatry 1990; 156: 357-62
147. Dhabhar FS, McEwen BS, Spencer RL. Effects of stress on immune cell distribution: dynamics and hormonal mechanisms. J Immunol 1995; 154: 5511-27
148. Jansen LMC, Gispen-de Wied CC, Gaderman PJ, et al. Blunted cortisol response to a psychosocial stressor in schizophrenia. Schizophr Res 1998; 33: 87-94
149. Jansen LMC, Gispen-de Wied CC, Kahn RS. Selective impairments in the stress response in schizophrenic patients. Psychopharmacology 2000; 149: 319-25
150. Gispen-de Wied CC. Stress in schizophrenia: an integrative view. Eur J Pharmacol 2000; 405: 375-84
151. Haack M, Hinze-Selch D, Fenzel T, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission. Effects of confounding factors and diagnosis. J Psychiatr Res 1999; 33: 407-18
152. Hinze-Selch D, Pollmächer T. In vitro cytokine secretion in individuals with schizophrenia: results, confounding factors and implications for further research. Brain Behav Immun 2001; 15: 282-318
153. Kanner L. Autistic disturbances of affective contact. Nerv Child 1943; 2: 217-50
154. Bayley A, Philips W, Reutter M. Autism: towards an integration of clinical, genetic, neuropsychological and neurobiological perspectives. J Child Psychol Psychiatry 1996; 37: 89-126
155. Trottier G, Srivastava L, Walker C. Etiology of infantile autism: a review of recent neurological research. J Psychiatry Neurosci 1999; 24: 103-32
156. Veenstra-Vanderweele J, Christian SL, Cook Jr EH. Autism as a paradigmatic complex genetic disorder. Annu Rev Genomics Hum Genet 2004; 5: 379-405
157. Korvatska E, Van de Water J, Anders TF, et al. Genetic and immunologic considerations in autism. Neurobiol Dis 2002; 9: 107-25
158. Lamb JA, Moore J, Bailey A, et al. Autism: recent molecular genetic advances. Hum Mol Genet 2000; 9: 861-8
159. Maestrini E, Paul A, Monaco AP, et al. Identifying autism susceptibility genes. Neuron 2000; 28: 19-24
160. VanGent T, Heijnen CJ, Treffers PDA. Autism and the immune system. J Child Psychol Psychiatry 1997; 38: 337-49
161. Gupta S. Immunological treatments of autism. J Autism Dev Disord 2000; 30: 475-9
162. Zimmerman AW. Immunological treatments for autism: in search of reasons for promising approaches. J Autism Dev Disord 2000; 30: 481-4
163. Ashwood P, Van de Water J. A review of autism and the immune response. Clin Dev Immunol 2004; 11: 165-74
164. Krause I, He XS, Gershwin E, et al. Brief report: immune factors in autism: a critical review. J Autism Dev Disord 2002; 32: 337-45
165. Sweeten TL, Posey DJ, McDougle CJ. High blood monocyte counts and neopterin levels in children with autistic disorder. Am J Psychiatry 2003; 160: 1691-3
166. Chez MG, Chin K, Hung PC. Immunizations, immunology and autism. Semin Pediatr Neurol 2004; 11: 214-7
167. Warren RP, Margaretten NC, Pace NC, et al. Immune abnormalities in patients with autism. J Autism Dev Disord 1986; 16: 189-97
168. Warren RP, Foster A, Margaretten NC. Reduced natural killer cell activity in autism. J Am Acad Child Adolsec Psychiatry 1987; 26: 333-5
169. Plioplys AV, Greaves A, Kazemi K, et al. Lymphocyte function in autism and Rett syndrome. Neuropsychobiology 1994; 29: 12-6
170. Denny DR, Frei BW, Gaffney GR. Lymphocyte subsets and interleukin-2 receptors in autistic children. J Autism Dev Disord 1996; 26: 87-97
171. Harrison KL, Pheasant AE. Analysis of urinary pterins in autism [abstract]. Biochem Soc Trans 1995; 23: 603S
172. Messahal S, Pheasant AE, Pall H, et al. Urinary levels of neopterin and biopterin in autism. Neurosci Lett 1998; 241: 17-20
173. Gupta S, Aggarwal S, Heads C. Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics. J Autism Dev Disord 1996; 26: 439-52
174. Vojdani A, Campbell AW, Anyanwu E, et al. Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. J Neuroimmunol 2002; 129: 168-77
175. Gupta S, Lee T, Aggarval S. Alterations in Th1 and Th2 subsets of CD4+ and CD8+ T-cells in autism. J Neuroimmunol 1998; 14: 499-504
176. Jyonouchi H, Sun SN, Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol 2001; 120: 170-9
177. Warren RP, Singh VK, Averett RE, et al. Immunogenetic studies in autism and related disorders. Mol Chem Neuropathol 1996; 28: 77-81
178. Torres AR, Maciulis A, Stubbs EG, et al. The transmission disequilibrium test suggests that HLA-DR4 and DR13 are linked to autism spectrum disorder. Hum Immunol 2002; 63: 311-6
179. Ferrante P, Saresella M, Guerini FR, et al. Significant association of HLA A2-DR11 and CD4 naive decrease in autistic children. Biomed Pharmacother 2003; 57: 372-4
180. Warren RP, Singh VK, Cole P, et al. Increased frequency of the null allele at the complement C4B locus in autism. Clin Exp Immunol 1991; 83: 438-40
181. Warren RP, Sing P, Cole P, et al. Possible association of the extended MHC haplotype B44-SC30-DR4 with autism. Immunogenetics 1992; 36: 203-7
182. Broadley SA, Dean J, Sawcer SJ, et al. Autoimmune disease in first-degree relatives of patients with multiple sclerosis. Brain 2000; 123: 1102-11
183. Prahalad S, Shear ES, Ghompson D, et al. Increased prevalence of familial autoimmunity in simplex and multiplex families with juvenile rheumatoid arthritis. Arthritis Rheum 2002; 46: 1851-6
184. Sweeten TL, Bowyer SL, Posey DJ, et al. Increased prevalence of familial autoimmunity in probands with pervasive development disorders. Pediatrics 2003; 112: 420-4
185. Comi AM, Zimmerman AW, Frye VH, et al. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J Child Neurol 1999; 14: 388-94
186. Singh VK, Warren RP, Odell JD, et al. Antibodies to myelin basic protein in children with autistic behaviour. Brain Behav Immunol 1993; 7: 97-103
187. Singh VK, Fudenberg HH, Emerson D, et al. Immunodiagnosis and immunotherapy in autistic children. Ann N Y Acad Sci 1988; 540: 602-4
188. Todd RD, Ciaranello RD. Demonstration if inter- and intraspecies differences in serotonin binding sites by antibodies from an autistic child. Proc Nat Acad Sci U S A 1985; 82: 612-6
189. Cook Jr EH, Perry BD, Dawson G, et al. Receptor inhibition by immunoglobulins: specific inhibition by autistic children, their relatives and control subjects. J Autism Dev Disord 1993; 23: 67-78
190. Yuwiler A, Shih JC, Chen CH, et al. Hyperserotoninemia and antiserotonin antibodies in autism and other disorders. J Autism Dev Disord 1992; 22: 33-45
191. Connolly AM, Chez MG, Pestronk A, et al. Serum antibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorder. J Pediatr 1999; 134: 607-13
192. Silva SC, Correia C, Fesel C, et al. Autoantibody repertoires to brain tissue in autism nuclear families. J Neuroimmunol 2004; 152: 176-82
193. Singh VK, Jensen RL. Elevated levels of measles antibodies in children with autism. Pediatr Neurol 2003; 28: 292-4
194. Vojdani A, Bazargan M, Vojdani E, et al. Heat shock protein and gliadin peptide promote development of peptidase antibodies in children with autism and patients with autoimmune disease. Clin Diagn Lab Immun 2004; 11: 515-24
195. Muscat C, Bertotto A, Agea E, et al. Expression and functional role of 1F7 (CD26) antigen on peripheral blood and synovial fluid cells in rheumatoid arthritis patients. Clin Exp Immunol 1994; 98: 252-6
196. Nakao H, Eguchi K, Kawakami A, et al. Increment of Tal positive cells in peripheral blood from patients with rheumatoid arthritis. J Rheumatol 1989; 16: 904-14
197. Binstock T. Intra-monocyte pathogens delineate autism subgroups. Med Hypotheses 2001; 56: 523-31
198. Ciaranello AL, Ciaranello RD. The neurobiology of infantile autism. Annu Rev Neurosci 1995; 18: 101-28
199. Hornig M, Weissenbock H, Horscroft N, et al. An infection-based model of neurodevelopmental damage. Proc Natl Acad Sci U S A 1999; 96: 12102-7
200. Pletnikov MV, Moran TH, Carbone KM. Borne disease virus infection of the neonatal rat: developmental brain injury model of autism spectrum disorders. Front Biosci 2002; 7: d593-607
201. Gimpl G, Fahrenhol F. The oxytocin receptor system structure, function and regulation. Physiol Rev 2001; 81: 629-83
202. Young MR, Kut JL, Coogan MP, et al. Stimulation of splenic T-lymphocyte function by endogenous serotonin and by low dose exogenous serotonin. Immunology 1993; 80: 395-400
203. Kut JL, Young MR, Crayton JW, et al. Regulation of murine T lymphocyte function by spleen cell-derived and exogenous serotonin. Immunopharmacol Immunotoxicol 1992; 14: 783-96
204. Chugani DC, Muzik O, Rothermel R, et al. Altered serotonin synthesis in the dentatothalamocortical pathways in autistic boys. Ann Neurol 1997; 42: 666-9
205. Modahl C, Green L, Feind D, et al. Plasma oxytocin levels in autistic children. Biol Psychiatry 1998; 43: 270-7
206. Green L, Fein D, Modahl C, et al. Oxytocin and autistic disorder: alterations in peptide forms. Biol Psychiatry 2001; 50: 609-13
207. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoidnodular, hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998; 351: 637-41
208. Turner M, Barnby G, Bailey A. Genetic clues to the biological basis of autism. Mol Med Today 2000; 6: 238-44
209. Binstock T. Intra-monocyte pathogens delineate autism subgroups. Med Hypotheses 2001; 56: 523-31
210. Money J, Bobrow NA, Clark FC. Autism and autoimmune disease: a family study. J Autism Child Schizophr 1971; 1: 146-60
211. Burger RA, Warren RP. Possible immunogenetic basis for autism. Ment Retard Dev Disabil Res Rev 1998; 4: 137-41
212. Croonenberghs J, Bosmans E, Deboutte D, et al. Activation of the inflammatory response in autism. Neuropsychobiology 2002; 45: 1-6
213. Wakefield AJ, Pulestron JM, Montgomery SM, et al. Review article: the concept of entero-colonic encephalopathology, autism and opioid receptor ligands. Aliment Pharmacol Ther 2002; 16: 636-74
214. Halsey NA, Hyman SL. Conference writing panel, measles-mumps-rubella vaccine and autistic spectrum disorder: report from the new challenges in childhood immunizations conference convened in Oak Brook, Illinois. June 12-13, 2000. Pediatrics 2001; 107: E84
215. Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med 2002; 347: 1477-82
216. Taylor B, Miller E, Lingam R, et al. Measles, mumps and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ 2002; 324: 393-6
217. Makela A, Nuorti JP, Peltola H. Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics 2002; 110: 957-63
218. Taylor B, Miller E, Farrington CP, et al. Autism and measles, mumps and rubella vaccine: no epidemiological evidence for a causal association. Lancet 1999; 353: 2026-9
219. Hviid A, Stellfeld M, Wohlfahrt J, et al. Association between thimerosal-containing vaccine and autism. JAMA 2003; 290: 1763-6
220. Stehr-Green P, Tull P, Stellfeld M, et al. Autism and thimerosal-containing vaccines: lack of consistent evidence for an association. Am J Prev Med 2003; 25: 101-6
221. Murch SH, Anthony A, Casson DH, et al. Retraction of an interpretation. Lancet 2004; 363: 750
222. Zorilla EP, Luborsky L, McKay JR, et al. The Relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001; 15: 199-226
223. Herbert TB, Cohen S. Depression and immunity: a meta-analytic review. Psychol Bull 1993; 113: 472-86
224. Weisse CS. Depression and immunocompetence: a review of the literature. Psychol Bull 1992; 111: 475-89
225. Zorilla EP, Cannon TD, Kessler J, et al. Leukocyte differentials predict short-term clinical outcome following antipsychotic treatment in schizophrenia. Biol Psychiatry 1998; 43: 887-96
226. Schleifer SJ, Keller SE, Meyerson AT, et al. Lymphocyte function in major depressive disorder. Arch Gen Psychiatry 1984; 41: 484-6
227. Irwin M. Immune correlates of depression. In: Dantzer R, Wollman EE, Yirmiya R, editors. Cytokines, stress and depression. New York: Kluwer Academic/Plenum Publishers, 1999: 1-24
228. Sluzewska A. Indicators of immune activation in depressed patients. In: Dantzer R, Wollman EE, Yirmiya R, editors. Cytokines, stress and depression. New York: Kluwer Academic/Plenum Publishers, 1999: 59-73
229. Maes M. Major depression and activation of the inflammatory response system. In: Dantzer R, Wollman EE, Yirmiya R, editors. Cytokines, stress and depression. New York: Kluwer Academic/Plenum Publishers, 1999: 25-46
230. Kemeny ME, Weiner H, Taylor SE, et al. Repeated bereavement, depressed mood, and immune parameters in HIV sero positive and seronegative gay men. Health Psychol 1994; 13: 14-24
231. Crook TH, Miller NW. The challenge of Alzheimer's disease. Am Psychol 1985; 40: 1245-50
232. Fiore J, Becker J, Coppel DB. Social network interactions: a buffer or a stress? Am J Community Psychol 1983; 11: 423-9
233. Olff M. Stress, depression and immunity: the role of defense and coping styles. Psychiatry Res 1999; 85: 7-15
234. Barefoot JC, Brummett BH, Helms MJ, et al. Depressive symptoms and survival of patients with coronary artery disease. Psychosom Med 2000; 62: 790-5
235. Wulsin LR, Vaillant GE, Wells VE. A systematic review of the mortality of depression. Psychosom Med 1999; 61: 6-17
236. Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry 1998; 155: 4-11
237. Lesperance F, Frasure-Smith N, Juneau M, et al. Depression and 1-year prognosis in unstable angina. Arch Intern Med 2000, 60
238. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology and treatment. Arch Gen Psychiatry 1998; 55: 580-92
239. Kagan J, Snidman N, Julia-Sellers M, et al. Temperament and allergic symptoms. Psychosom Med 1991; 53: 332-40
240. Parker JC, Smarr KL, Angelone EO, et al. Psychological factors, immunologic activation and disease activity in rheuma toid arthritis. Arthritis Care Res 1992; 5: 196-201
241. Cohen S, Doyle WJ, Skoner DP. Psychological stress, cytokine production, and severity of upper respiratory illness. Psychosom Med 1999; 61: 175-80
242. Cohen S, Tyrrell DA, Smith AP. Psychological stress and susceptibility to the common cold. N Engl J Med 1991; 325: 606-56
243. Cohen S, Williamson G. Stress and infectious disease in humans. Psychol Bull 1991; 109: 5-24
244. Kiecolt-Glaser JK, Glaser R, Gravenstein S, et al. Chronic stress alters the immune response to influenza virus vaccine in older adults. Proc Natl Acad Sci U S A 1996; 93: 3043-7
245. Stein M, Miller AH, Trestman RL. Depression, the immune system and health and illness. Arch Gen Psychiatry 1991; 48: 171-7
246. Jung W, Irwin M. Reduction of natural killer cytotoxic activity in major depression. interaction between depression and ciga rette smoking. Psychosom Med 1999; 61: 263-70
247. Dinan T. Glucocorticoids and the genesis of depressive illness: a psychobiological model. Br J Psychiatry 1994; 164: 365-71
248. Tilders FJH, Schmidt ED. Cross-sensitization between immune and non-immune stressors: a role in the etiology of depression? In: Dantzer R, Wollman EE, Yirmiya R, editors. Cytokines, stress and depression. New York: Kluwer Academic/Plenum Publishers, 1999: 179-97
249. Smith RS. The macrophage theory of depression. Med Hypothesis 1991; 35: 298-306
250. Maes M, Meltzer H, Bosmans E, et al. Increased plasma concen trations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995; 34: 301-9
251. Maes M, Smith R, Scharpé S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 1995; 20: 11-6
252. Herrmann C, Brand-Driehorst S, Kaminsky B, et al. Diagnostic groups and depressed mood as predictors of 22-month mortality in medical inpatients. Psychosom Med 1998; 60: 570-7
253. Leonard BE, Song C. Changes in the immune system in rodent models of depression. Int J Neuropsychopharmacol 2002; 5: 345-6
254. Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-response systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999; 4: 317-27
255. Vitkovic L, Konsman JP, Bockaert J, et al. Cytokine signals propagate through the brain. Mol Psychiatry 2000; 5: 605-15
256. Carpenter LL, Heninger GR, Malison RT, et al. Cerebrospinal fluid interleukin (IL)-6 unipolar major depression. J Affect Disord 2004; 79: 285-9
257. Irwin M. Psychoneuroimmunology of depression: clinical implications. Brain Behav Immunity 2002; 16: 1-16
258. Song C, Leonard BE. Fundamentals of psychoimmunology. New York: J Wiley & Sons Ltd, 2000
259. Widner B, Laich A, Sperner-Unterweger B, et al. Neopterin production, tryptophan degradation, and mental depression: what is the link? Brain Behav Immunity 2002; 16: 590-5
260. Maes M, Bosmans E, Meltzer HY, et al. Interleukin-1β: a putative mediator of HPA-axis hyperactivity in major depression? Am J Psychiatry 1993; 150: 1189-93
261. Song C, Lin A, Bonaccorso S, et al. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J Affect Disord 1998; 49: 211-9
262. Murr C, Widner B, Sperner-Unterweger B, et al. Immune reaction links disease progression in cancer patients with depression. Med Hypothesis 2000; 55 (2): 137-40
263. Guillemin GJ, Kerr SJ, Brew BJ. Involvement of quinolinic acid in AIDS dementia complex. Neurotox Res 2005; 7: 103-23
264. Huengsberg M, Winer JB, Gompels M, et al. Serum kynurenine-to-tryptophan ration increase with progressive disease in HIV-infected patients. Clin Chem 1998; 44: 858-62
265. Hansen AM, Driussi C, Turner V, et al. Tissue distribution of indoleamine 2,3-dioxygenase in normal and malaria-infected tissue. Redox Rep 2000; 5: 112-5
266. Corcos M, Guilboud O, Hjalmarsson L, et al. Cytokines and depression: an analogic approach. Biomed Pharmacother 2002; 56: 105-10
267. Van Amsterdam JGC, Opperhuizen A. Nitric oxide and biopterin in depression and stress. Psychiatry Res 1999; 85: 33-8
268. Karatinos J, Rosse RB, Deutsch SI. The nitric oxide pathway: potential implications for treatment of neuropsychiatric disorders. Clin Neuropharmacol 1995; 18: 482-99
269. Park KG, Hayes PD, Garlick PJ, et al. Stimulation of lymphocyte natural cytotoxicity by L-arginine. Lancet 1991; 337: 645-6
270. Xiao L, Eneroth PH, Qureshi GA. Nitric oxide synthase pathway may mediate human natural killer cell cytotoxicity. Scand J Immunol 1995; 42: 505-11
271. Anisman H, Ravindran AV, Griffiths J, et al. Interleukin-1β production in dysthymia before and after pharmacotherapy. Biol Psychiatry 1999; 46: 1649-55
272. Rothermundt M, Arolt V, Peters M, et al. Inflammatory markers in major depression and melancholia. J Affect Disord 2001; 63: 93-102
273. Cassidy F, Wilson WH, Caroll BJ. Leukocytosis and hypoalbuminemia in mixed bipolar states: evidence for immune activation. Acta Psychiatr Scand 2002; 105: 60-4
274. Liu HC, Yang YY, Chou Y, et al. Immunologic variables in acute mania of bipolar disorder. J Neuroimmunol 2004; 150: 116-22
275. Breunis MN, Kupla RW, Nolen WA, et al. High numbers of circulating activated t-cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol Psychiatry 2003; 53: 157-65
276. Padmos RC, Bekris L, Knijff EM, et al. A high prevalence of organ-specific autoimmunity in patients with bipolar disorder. Biol Psychiatry 2004; 56: 476-82
277. Dickerson FB, Boronow JJ, Stellings C, et al. Infection with herbes simplex virus type 1 is associated with cognitive deficits in bipolar disorder. Biol Psychiatry 2004; 55: 588-93
278. Stastny J, Konstantinidis A, Schwarz MJ, et al. Effects of tryptophan depletion and catecholamine depletion on immune parameters in patients with seasonal affective disorder in remission with light therapy. Biol Psychiatry 2003; 53: 332-7
279. Haekstra R, Fekkes D, Van De Wetering BJM, et al. Effect of light therapy on biopterin, neopterin and tryptophan in patients with seasonal affective disorder. Psychiatr Res 2003; 120: 37-42
280. Ravindran AV, Griffiths J, Merali Z, et al. Influence of acute tryptophan depletion on mood and immune measures in healthy males. Psychoneuroendocrinology 1999; 24: 99-113
281. Irwin M. Neuroimmunology of disordered sleep in depression and alcoholism. Neuropsychopharmacology 2001; 25: S45-9
282. Irwin M, Clark C, Lennedy B, et al. Nocturnal catecholamines and immune function in insomniacs, depressed patients, and control subjects. Brain Behav Immunity 2003; 17: 365-72
283. Miller GE, Cohen S, Herbert TB. Pathways linking major depression and immunity in ambulatory female patients. Psychosom Med 1999; 61: 850-60
284. Koh KB, Lee BK. Reduced lymphocyte proliferation and interleukin-2 production in anxiety disorders [abstract]. Psychosom Med 1996; 58: 80
285. Zorilla E, Redei E, Derubeis RJ. Reduces cytokine levels in T-cell function in healthy males: relation to individual differences in subclinical anxiety. Brain Behav Immunity 1994; 8: 293-312
286. Andreoli A, Keller SE, Rabaeus M, et al. Immunity, major depression and panic disorder comorbidity. Biol Psychiatry 1992; 31: 869-908
287. Brambilla F, Bellodi L, Perna G, et al. Psychoimmunoendocrine aspects of panic disorder. Neuropsychobiology 1992; 26: 12-22
288. Schleifer SJ, Keller SE, Scott BJ, et al. Lymphocyte function in panic disorder [abstract]. Biol Psychiatry 1990; 27 Suppl. 9a: 66a
289. Marazziti D, Ambrogi F, Vanacore R, et al. Immune cell imbalance in major depressive and panic disorders. Neuropsychobi ology 1992; 26: 23-6
290. Rapaport MH, Stein MB. A preliminary study of serum cytokine and soluble interleukin-2 receptors in patients with panic disorder. Anxiety 1994; 1: 22-5
291. Rapaport MH. Circulating lymphocyte phenotypic surface markers in anxiety disorder patients and normal volunteers. Biol Psychiatry 1998; 43: 458-63
292. Koh KB. The relationship between stress and natural killer-cellactivity in medical college students. Korean J Psychosom Med 1993; 3: 3-10
293. Koh KB. Emotion and immunity. J Psychosom Res 1998; 45 (2): 107-15
294. Atanackovic D, Kröger H, Serke S, et al. Immune parameters in patients with anxiety or depression during psychotherapy. J Affect Disord 2004; 81: 201-9
295. Coplan JD, Tamir H, Calaprice D, et al. Plasma anti-serotonin and serotonin anti-idiotypic antibodies are elevated in panic disorder. Neuropsychopharmacology 1999; 20: 386-91
296. Watson R, Borgs P, Wite M, et al. Alcohol, immunomodulation, and disease. Alcohol Alcohol 1994; 29: 131-9
297. O'Hanlon M, Salter S, Scull D, et al. Neopterin levels in alcohol-dependent patients. Ann Clin Biochem 1996; 33: 536-9
298. Santos-Perez JL, Diez-Ruiz A, Luna-Casado L, et al. T-cell activation, expression of adhesion molecules and response to ethanol in alcoholic cirrhosis. Immunol Lett 1996; 50: 179-83
299. Cook RT. Alcohol abuse, alcoholism and damage to the immune system: a review. Alcohol Clin Exp Res 1998; 22: 1927-42
300. Cook RT, Garvey MJ, Booth BM, et al. Activated CD-8 cells and HLA DR expression alcoholics without liver disease. J Clin Immunol 1991; 11: 246-53
301. Irwin M, Caldwell C, Smith TL, et al. Major depression disorder, alcoholism and reduced natural killer cell cytotoxicity: role of severity of depressive symptoms and alcohol consumption. Arch Gen Psychiatry 1990; 47: 713-9
302. Motivala SJ, Dang J, Obradovic T, et al. Leptin and cellular and innate immunity in abstinent alcoholics and controls. Alcohol Clin Exp Res 2003; 27: 1819-24
303. Gonzalez-Quintela A, Gude F, Boquete O, et al. Association of alcohol consumption with total serum immunoglobin E levels and allergic sensitization in an adult population-based survey. Clin Exp Allergy 2003; 33: 199-205
304. Dominguez-Santalla MJ, Vidal C, Vinuela J, et al. Increased serum IgE in alcoholics: relationship with Th1/Th2 cytokine production by stimulated blood mononuclear cells. Alcohol Clin Exp Res 2001; 25: 1198-205
305. Charpentier B, Franco D, Paci L, et al. Deficient natural killer cell activity in alcohol cirrhosis. Clin Exp Immunol 1984; 58: 107-15
306. Cook RT, Vandersteen D, Ballas ZK, et al. Ethanol and natural killer cells: I. Activity and immunophenotype in alcohol humans. Alcohol Clin Exp Res 1997; 21: 974-87
307. Kronfol Z, Nair M, Hill E, et al. Immune function in alcoholism: a controlled study. Alcohol Clin Exp Res 1993; 17: 279-83
308. Schleifer SJ, Keller SE, Shiflett S, et al. Immune changes in alcohol-dependent patients without medical disorder. Alcohol Clin Exp Res 1999; 23: 1199-206
309. Szabo G, Mandreka P, Catalano D. Inhibition of superantigen-induced cell proliferation and monocyte IL-1 beta, TNF-alpha, and IL-6 production by acute ethanol treatment. J Leukoc Biol 1995; 58: 342-50
310. Szabo G, Mandrekar P, Girouard L, et al. Regulation of human psychobimonocyte functions and acute ethanol treatment: decreased tumor necrosis factor-alpha, interleukin-1betta and elevated interleukin-10 and transforming growth factor production. Alcohol Clin Exp Res 1996; 20: 900-7
311. Batey R, Cao Q, Masden G, et al. Decreased tumor necrosis factor-alpha and interleukin-1 alpha production from intrahepatic mononuclear cells in chronic ethanol consumption and upregulation by endotoxin. Alcohol Clin Exp Res 1998; 22: 150-6
312. Jerrells TR, Sibley DA, Slukvin II, et al. Effects of ethanol consumption on mucosal and systemic T-cell dependent immune responses to pathogenic microorganisms. Alcohol Clin Exp Res 1998; 22 (5 Suppl.): 212S-5S
313. Rivier C. Effect of acute alcohol treatment on the release of ACTH, corticosterone, and pro-inflammatory cytokines in response to endotoxin. Alcohol Clin Exp Res 1999; 23: 673-82
314. Friedman H. Alcohol effects on cytokine responses by immunocytes. Alcohol Clin Exp Res 1998; 22: 184S-7
315. Zisman DA, Strieter RM, Kunkel SL, et al. Ethanol feeding impairs innate immunity and alters the expression of Th1- and Th2-phenotype cytokines in murine Klebsiella pneumonia. Alcohol Clin Exp Res 1998; 22: 621-7
316. Omidvari K, Casey R, Nelson S, et al. Alveolar macrophage release of tumor necrosis factor in chronic alcoholics without liver disease. Alcohol Clin Exp Res 1998; 22: 567-72
317. Laso F, Lapena P, Madruga JI, et al. Alterations in tumor necrosis factor-alpha, interferon-gamma, and interleukin-6 production by natural killer cell-enriched peripheral blood pharmononuclear cells in chronic alcoholism: relationship with liver disease and ethanol intake. Alcohol Clin Exp Res 1997; 21: 1226-31
318. Song C, Lin A, De Jong R, et al. Cytokines in detoxified patients with chronic alcoholism without liver disease: increased monocytic cytokine production. Biol Psychiatry 1999; 45: 1212-6
319. Nicolaou C, Chatzipanagioutou S, Tzivos D, et al. Serum cytokine concentration in alcohol-dependent individuals without liver disease. Alcohol 2004; 32: 243-7
320. Irwin M, Miller C. Decreased natural killer cells responses and altered interleukin-6 and interleukin-10 production in alcoholism: an interaction between alcohol dependence and African-American ethnicity. Alcohol Clin Exp Res 2000; 24: 560-9
321. Irwin M. Effects of sleep and sleep loss on immunity and cytokines. Brain Behav Immun 2002; 16: 503-12
322. Irwin M, Rinetti G. Disordered sleep, nocturnal cytokines and immunity: interactions between alcohol dependence and African-American Ethnicity. Alcohol 2004; 32: 53-61
323. Redwine L, Dang J, Hall M, et al. Disordered sleep, nocturnal cytokines and immunity in alcoholics. Psychosom Med 2003; 65: 75-85
324. MacGregor RR. Alcohol and immune defence. JAMA 1986; 256: 1474-9
325. MacGregor RR, Lourin DB. Alcohol and infection. Curr Clin Top Infect Dis 1997; 17: 291-315
326. Nalpas B, Pol S, Thepot V, et al. ESBRA 1997 award lecture: relationship between excessive alcohol dringing and viral infections. Alcohol Alcohol 1998; 33: 202-6
327. Frank J, Witte K, Schrödl W, et al. Chronic alcoholism causes deleterious conditioning of innate immunity. Alcohol Alcohol 2004; 39: 386-92
328. Diaz LE, Montero A, Conzalez-Gross M, et al. Influence of alcohol consumption on immunological status: a review. Eur J Clin Nutr 2002; 56 Suppl. 3: S50-3
329. Jerrells TR. Role of activated CD8+ cells in the initiation and continuation of hepatic damage. Alcohol 2002; 27: 47-52
330. McClain CJ, Hill DB, Song Z, et al. Monocyte activation in alcoholic liver disease. Alcohol 2002; 27: 53-61
331. Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev 2003; 16: 209-19
332. Friedman H. Drugs of abuse as possible co-factors in AIDS progression: summary of panel discussion. Adv Exp Med Biol 1996; 402: 225-8
333. Pruett SB, Han YC, Fuchs BA. Morphine suppresses primary humoral immune responses by a predominantly indirect mechanism. J Pharmacol Exp Ther 1992; 262: 923-8
334. Sei Y, McIntyre T, Fide E, et al. Inhibition of calcium mobilization is an early event in opiate-induced immunosuppression. FASEB J 1991; 5: 2194-9
335. Shavit Y, Depaulis A, Martin FC, et al. Involvement of brain opiate receptors in the immune-suppressive effect of morphine. Proc Natl Acad Sci U S A 1986; 83: 7114-7
336. Massi P, Fuzio D, Vigano D, et al. Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity. Eur J Pharmacol 2000; 387: 343-7
337. Lee SF, Newton C, Widen R, et al. Differential expression of cannabinoid CB2 receptor mRNA in mouse immune cell sub populations and following B cell stimulation. Eur J Pharmacol 2001; 423: 235-41
338. Pellegrino TC, Dunn KL, Bayer BM. Mechanisms of cocaine induced decreases in immune cell function. Int Immunopharmacol 2001; 1: 665-75
339. Roy S, Balasubramanian S, Sumandeep S, et al. Morphine directs T cells toward T(H2) differentiation. Surgery 2001; 130: 304-9
340. Hermosillo-Romo D, Brey RL. Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Best Pract Res Clin Rheumatol 2002; 16: 229-44
341. Hermosillo-Romo D, Brey RL. Neuropsychiatric involvement in systemic lupus erythematosus. Curr Rheumatol Rep 2002; 4: 337-44
342. Weiner SM, Peter HH. Neuropsychiatric involvement in systemic lupus erythematosus. Part 1: clinical presentation and pathogenesis. Med Klin (Munich) 2002; 97: 730-7
343. Sacktor NC. Advances in the treatment of HIV dementia. AIDS Read 1999; 9: 57-60
344. Albright AV, Soldan SS, Gonzalez-Scarano F. Pathogenesis of human immunodeficiency virus-induces neurological disease. J Neurovirol 2003; 9: 222-7
345. Wersinger C, Sidhu A. Inflammation and Parkinson's disease. Curr Drug Targets Inflamm Allergy 2002; 1: 221-42
346. Selkoe DJ, Schenk D. Alzheimer disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003; 43: 545-84
347. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoporotein E, dementia, and cortical deposition of β-amyloid protein. N Engl J Med 1995; 333: 1242-7
348. Blasko I, Grubek-Loebenstein B. Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease. Drugs Aging 2003; 2: 101-13
349. Leonard BE. The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 767-80
350. Ringheim GE, Conant K. Neurodegenerative disease and the neuroimmune axis (Alzheimer's and Parkinson's disease, and viral infections). J Neuroimmunol 2004; 147: 43-9
351. Lahiri DK, Nall C. Promoter activity of the gene encoding the beta-amyloid precursor protein is up-regulated by growth factors, phorbol ester, retinoic acid and interleukin-1. Mol Brain Res 1995; 32: 233-40
352. Ringheim GE, Szczepanik AM, Burgher KL, et al. Transcriptional inhibition of the Alzheimer's disease beta-amyloid pre-cursor protein by interferon-gamma. Biochem Biophys Res Commun 1996; 224: 246-51
353. Blasko I, Marx F, Steiner E, et al. TNF-alpha plus IFN-gamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J 1999; 13: 63-8
354. Blasko I, Veerhius R, Stamper-Kountchev M, et al. Costimulatory effects of interferon-gamma and interleukin-1 beta or tumor necrosis factor alpha on the synthesis of A-beta-1-40 and A-beta-1-42 by human astrocytes. Neurobiol Dis 2000; 7: 682-9
355. Breitner JCS, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995; 16: 523-30
356. Stewart WF, Kawas C, Corrada M, et al. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997; 48: 626-32
357. Itzhaki RF, Wozniak MA. Alzheimer's disease, the neuroimmune axis and viral infection. J Neuroimmunol 2004; 156: 1-2
358. Müller N, Riedel M, Scheppack C, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002; 159: 1029-34
359. Levine J, Susnovski M, Handzel ZT, et al. Treatment of schizophrenia with an immunosuppressant. Lancet 1994; 34: 59-60
360. Maes M, Christophe A, Bosmans E, et al. In humans, serum polyunsaturated fatty acid levels predict the response of proinflammatory cytokines to psychologic stress. Biol Psychiatry 2000; 47: 910-20
361. Zhang XY, Zhou DF, Cao LY, et al. Changes in serum interleukin-2, -6 and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry 2004; 65: 940-7
362. Gupta S. Immunological treatments for autism. J Autism Dev Disord 2000; 30: 475-9
363. Fudenberg HH, Singh VK, Emerson D, et al. Immunotherapy for autistic syndrome. J Neuroimmunol 1987; 16: 58
364. Gupta S, Rimland B, Shilling PD. Pentoxyfylline: a brief review and rationale for its possible use in the treatment of autism. J Child Neurol 1996; 11: 501-4
365. Plioplys AV. Intravenous immunoglobulin treatment of children with autism. J Child Neurol 1998; 13: 79-82
366. DelGiudice-Asch G, Simon L, Schmeidler J, et al. Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism. J Autism Dev Disord 1999; 29: 157-60
367. Mott SH, Weinstein SL, Conry JA, et al. Pervasive developmental disorder/autism versus Landau-Kleffner syndrome: steroid-responsive encephalopathy characterized by language and social interactive impairment [abstract]. Ann Neurol 1996; 40: 332
368. Matarazzo EB. Treatment of late onset autism as a consequence of probable autoimmune processes related to chronic bacterial infection. World J Biol Psychiatry 2002; 3: 162-6
369. Deleplanque B, Neveu PJ. Immunological effects of neuropsychiatric substance. In: Guenounou M, editor. Forum on immunomodulators. Paris: John Libbey Eurotext, 1995: 287-302
370. Melia KR, Duman RS. Involvement of corticotropin-releasing factor in chronic stress regulation of the main noradrenergic system. Proc Natl Acad Sci U S A 1991; 88: 8382-6
371. Smith MA, Makino S, Altemus M, et al. Stress and antidepressants differentially regulate neurotrophin 3mRNA expression in the locus coeruleus. Proc Natl Acad Sci U S A 1995; 92: 8788-92
372. Xia Z, De Poere JW, Nassberger L. TCA's inhibit IL-1, IL-6 and TNF release in human blood monocytes in IL-2 and interferon in T-cells. Immunopharmacol 1996; 34: 27-37
373. Maes M, Song C, Lin A, et al. Immune and clinical correlates of psychological stress: induced production of interferon-gamma and IL-10 in humans. In: Plotnikoff NP, editor. Cytokines, stress and immunity. Boca Raton (FL): CRC-Press, 1999: 106-13
374. Suzuki E, Shintani F, Kamba S, et al. Induction of interleukin-1 beta and interleukin-1 receptor antagonist mRNA by chronic treatment with various psychotropics is widespread areas of rat brain. Neurosci Lett 1996; 215: 201-4
375. Rylett RJ, Williams LF. Role of neurotrophic factor in choliner gic-neurone function in the adult and aged CNS. Trends Neurosci 1994; 17: 486-90
376. Cellerino A, Maffei L. The action of neurotrophins in the development and plasticity of the visual cortex. Prog Neurobiol 1996; 49: 53-71
377. Berardi N, Pizzorusso T, Maffei L. Critical periods during sensory development. Curr Opin Neurobiol 2000; 10: 138-45
378. Angelucci F, Mathe AA, Aloe L. Neutrotrophic factors in CNS disorders: findings in rodent models of depression and schizophrenia. Prog Brain Res 2004; 146: 151-65
379. Rajakumar N, Leung LS, Ma J, et al. Altered neurotrophin receptor function in the developing prefrontal cortex leads to adult-onset dopaminergic hyperresponsivity and impaired prepulse inhibition of acoustic startle. Biol Psychiatry 2004; 55: 797-803
380. Pirildar S, Gonul AS, Taneli F, et al. Low serum levels of brain derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 709-13
381. Durany N, Thome J. Neurotrophic factors and the pathophysiology of schizophrenic psychoses. Eur Psychiatry 2004; 19 (6): 326-37
382. Besser M, Wank R. Clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neutrophin-3 mRNS by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol 1998; 162: 6303-6
383. Wank R. Schizophrenia and other mental disorders require long-term adoptive immunotherapy. Med Hypotheses 2002; 59: 154-8
384. Castrén E. Neurotrophins as mediators of drug effects on mood, addiction, and neuroprotection. Mol Neurobiol 2004; 29: 289-301
385. Manji HK, Quiroz JA, Sporn J, et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003; 53: 707-42
386. Horrobin DF. Essential fatty acids, psychiatric disorders and neuropathies. In: Horrobin DF, editor. Omega-6 essential fatty acids: pathophysiology and roles in clinical medicine. New York: Wiley-Liss, 1990: 305-20
387. Peet M, Morphy B, Shay J, et al. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 1998; 43: 315-9
388. Maes M, Christophe A, Delanghe J, et al. Lowered ω3 polyun-saturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatr Res 1999; 85: 275-91
389. Stoll AL, Severus E, Freeman M, et al. Omega 3 fatty acids in bipolar disorders. Arch Gen Psychiatry 1999; 56: 407-12
390. Edwards R, Peet M, Shay J, et al. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 1998; 48: 149-55
391. Logan AC. Neurobehavioral aspects of omega-3 fatty acids: possible mechanisms and therapeutic value in major depression. Altern Med Rev 2003; 8: 410-25
392. Wu A, Ying Z, Gomez-Pinilla F. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J Neurotrauma 2004; 21: 1457-67
393. Zavala F. Benzodiazepines, anxiety and immunity. Pharmacol Ther 1997; 75: 199-216
394. Nagy LE. Recent insights into the role of the innate immune system in the development of alcoholic liver disease. Exp Biol Med 2003; 228: 882-90
395. Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev 2003; 16: 209-19
396. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-7
397. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916-9
398. Senior K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol 2002; 1 (1): 3
399. Schenk D. Opinion: Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 2002; 3: 824-8
400. Hock C, Konietzko U, Papassotiropoulos A, et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med 2002; 8: 1270-5
401. Nicoll JAR, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after iimmunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448-52
402. Monsonego A, Weiner H. Immunotherapeutic approaches to Alzheimer's disease. Science 2003; 302: 834-8
403. Dodel RC, Hampel H, Du Y. Immunotherapy for Alzheimer's disease. Lancet Neurol 2003; 2: 215-20
404. Heppner FL, Gandy S, McLaurin JA. Current concepts and future prospects for Alzheimer disease vaccines. Alzheimer Dis Assoc Disord 2004; 18: 38-43
405. Breitner JC, Zandi PP. Do nonsteroidal anti-inflammatory drugs reduce the risk of Alzheimer's disease? N Engl J Med 2001; 345: 1567-8
406. in t'Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515-21
407. Anthony JC, Breitner JC, Zandi PP, et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache Country study. Neurology 2000; 54: 2066-71
408. VanGool WA, Aisen PS, Eikelenboom P. Anti-inflammatory therapy in Alzheimer's disease: is hope still alive? J Neurol 2003; 250: 788-92